Development of Peptide Entry Inhibitors Targeting the Endosomal Receptor NPC1 Binding Site of Orthoebolavirus
Pathogens · 16.06.2026 · 15 (6) · 640
DOI: 10.3390/pathogens15060640 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, online erschienen am 16.06.2026. Verfasst von Leah Liu Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Veterinary Medicine and Biomedical Sciences, Nebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE 68588, USA. Hauptthemen laut MEDLINE: Virus Internalization, Peptides, Ebolavirus, Antiviral Agents. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Orthoebolavirus causes severe Ebola virus disease (EVD) and deadly outbreaks in humans. This infection occurs through macropinocytosis and trafficking to late endosomes or lysosomes that utilize the receptor Niemann–Pick C1 (NPC1) to enter the cell cytoplasm. We designed peptide inhibitors based on the NPC1 receptor to target the NPC1 binding site to block viral entry. The results indicated that the ligand-based peptide inhibitors showed potent inhibition activities in vitro studies against pseudotyped or replication-competent Orthoebolavirus. Therefore, we further evaluated one of them in a mouse model challenged with mice-adapted Ebola viruses, which showed some protection efficacy compared with the control group. This study suggests that ligand-based peptides are encouraging inhibitors in the development of inhibitors against Ebola virus infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Veterinary Medicine and Biomedical Sciences, Nebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE 68588, USA.
- Texas Biomedical Research Institute, 8715 W. Military Drive, San Antonio, TX 78227, USA.
- National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 02115, USA.
- Nonclinical Pathology Services, LLC, 5920 Clubhouse Pointe Dr., Medina, OH 44256, USA.
- College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA.
ORCID-Profile: Kendra Alfson, J J Patten, Sean N Avedissian, Robert A Davey, Ricardo Carrion, Shi-Hua Xiang
Förderung
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Wang, L. L., Alfson, K., Patten, J. J., Mattix, M. E., Goez-Gazi, Y., Avedissian, S. N., Davey, R. A., Carrion, R., & Xiang, S. H. (2026). Development of Peptide Entry Inhibitors Targeting the Endosomal Receptor NPC1 Binding Site of Orthoebolavirus. Pathogens, 15(6), 640. https://doi.org/10.3390/pathogens15060640
Vancouver
Wang LL, Alfson K, Patten JJ, Mattix ME, Goez-Gazi Y, Avedissian SN, et al. Development of Peptide Entry Inhibitors Targeting the Endosomal Receptor NPC1 Binding Site of Orthoebolavirus. Pathogens. 2026;15(6):640. doi:10.3390/pathogens15060640
BibTeX
@article{Wang2026,
author = {Wang, Leah Liu and Alfson, Kendra and Patten, J J and Mattix, Marc E and Goez-Gazi, Yenny and Avedissian, Sean N and Davey, Robert A and Carrion, Ricardo and Xiang, Shi-Hua},
title = {Development of Peptide Entry Inhibitors Targeting the Endosomal Receptor NPC1 Binding Site of Orthoebolavirus},
journal = {Pathogens},
year = {2026},
volume = {15},
number = {6},
pages = {640},
doi = {10.3390/pathogens15060640}
}
EUVIMED